CinRx Pharma was launched in September of 2015 to transform the development of innovative therapies addressing substantial unmet medical needs. With leading CRO Medpace as a strategic partner, CinRx leverages its cost-efficient structure while having access to global clinical development expertise and networks of advisors, critical understanding of the evolving regulatory environment, and industry-leading track records of execution across all stages of R&D.
CinRx’s therapeutic pipeline focuses on innovative and disruptive new molecular entities (NMEs). CinRx pursues an expedited path of development to achieve significant value inflection points for each of its programs. Once a compound has demonstrated clinical and commercial value, CinRx will determine the optimal strategy to bring the product to patients.
Currently, CinRx has four compounds advancing in its R&D portfolio, and has ongoing discussions for additional acquisitions of products and/or collaborative agreements with other partners. Each product candidate is being developed within its own business unit, a corporate structure that helps mitigate risk and allows flexible redeployment of assets, as needed.
most recently served as Teva’s Chief Medical Officer and was responsible for developing and overseeing the New Therapeutic Entities (NTEs) initiative across all therapeutic areas. During his career, Jon has been involved in developing hundreds of drugs from protocol design to global submission in various therapeutic areas, including cardio-metabolic, CNS, GI, oncology and infectious disease. Prior to joining Teva, Jon served as Executive Vice President, Head of Medical & Regulatory at Medpace, a global leader in research-based drug and device development. He trained in Internal Medicine and Cardiology at Harvard Medical School and was a member of the cardiology faculty at Yale Medical School. Jon is also a co-founder of the Metabolic & Atherosclerosis Research Center in Cincinnati, US.
most recently served as the Vice President of Research and Development, NTEs at Teva where she was responsible for developing over 20 repurposed products across multiple therapeutic areas. Catherine has over 19 years of experience in drug development including clinical research, business development and seed stage funding. She’s worked for companies such as Medpace, Merck, Ethicon and CincyTech.
recently served as the Senior Director of Product Development at Teva Pharmaceuticals where he was the co-inventor of over 20 patents. He has over 24 years of formulation product development and drug delivery experience. He’s an expert in early stage development, pre-formulation, preclinical formulation, clinical formulation, clinical manufacture, process development and technology transfer to commercial sites. Piyush also has strong expertise in oral and injectable dosage forms for small molecules, peptides, proteins and antibodies.
recently spent 8 years at CincyTech, a seed stage investment fund. At CincyTech, he focused on new company investment, portfolio company management, and internal operations and was participated in over 60 new company financings. CinyTech portfolio companies included AssureX Health (purchased by Myriad Genetics), Enable Injections, Akebia Therapeutics (NASDAQ: AKBA), and Blue Ash Therapeutics (purchased by Forest Laboratories). He received his Master’s in Finance from the University of Cincinnati and his Bachelor’s in Business Administration, specializing in Finance and Marketing, from Washington University in St. Louis.
has over 25 years of experience in the pharmaceutical industry and is experienced in both Sales and Research. She spent 21 years at Merck & Co. Inc. working in Merck Research Labs as a CRA and Trainer and in Global Human Health in various sales management roles. She most recently served as Associate Director of Sales where she provided leadership for sales teams and effectively allocated resources to drive execution of sales and marketing plans. Donna also served as Program Manager at Medpace where she was responsible for oversight of numerous global clinical trials.
Dr. Brian Murphy is board-certified in infectious disease, internal medicine, as well as pediatrics, and brings more than 15 years of leadership in clinical trial and drug development to the CinRx team. He has most recently served as Vice President of Medical Affairs at Medpace, CRO and therapeutic lead for the Infectious Diseases therapeutic franchise. Dr. Murphy has worked with large and small biopharmaceutical companies, government agencies, public-private partnerships, and academic centers during the approval of multiple products across various therapeutic areas. In his academic career at the University of Kentucky he led multi-disciplinary, translational and clinical research projects sponsored by NIH (NIAID and NHLBI), CDC, Department of Defense, and pharma in a broad range of indications and patient populations at all phases of clinical development (pre-clinical through Phase IV). Dr. Murphy continues to uphold an academic appointment and clinical practice and maintains close ties with his clinical and research colleagues.
Jonathan Isaacsohn, MD, FACC President and CEO, CinRx
August Troendle, MD President and CEO, Medpace, Inc.
Stephen P. Ewald, JD General Counsel, Medpace, Inc.
Jesse J. Geiger, CPA Vice President, CFO and
Treasurer, Medpace, Inc.